Metabolic consequences of modern immunosuppressive agents in solid organ transplantation

Maintenance steroids

The broad spectrum immunosuppressive property of steroids necessitates its use in different clinical settings [Zsom et al. 2015]. However, more than any other maintenance agent, the metabolic impact of steroids has justifiably received the most attention in the literature. There are concerns on the role of steroid-related diabetic nephropathy on the late-onset attrition of renal allografts, and in the promotion of CV morbidity [Zsom et al. 2015]. For these reasons, transplant protocols are designed with the goal of reducing the cumulative dose of steroids [Zsom et al. 2015; Zhang et al. 2013; Knight and Morris, 2010]. Patients placed on such steroid-sparing regimen are characterized by higher rate of acute rejection episodes (AREs) and lower allograft function [Zhang et al. 2013; Knight and Morris, 2010]. Nevertheless despite the associated improvement in metabolic profiles, such protocols often failed to translate into a long-term allograft or patient survival.

Calcineurin inhibitor

With a selective deactivation of T-cell immune function, CNI is the most effective maintenance ISA used for the prevention of allograft rejection [Zsom et al. 2015; Casey and Meier-Kriesche, 2011]. Kidney Disease Improving Global Outcome (KDIGO) recommends TAC, MMF and optional use of steroids as the first line agents. TAC is prescribed to over 96% of patients at the time of hospital discharge for transplant surgery [Rush, 2013]. Although TAC shared a similar mechanism of action with CsA, it has a lower acute rejection (AR) rate and produces a more favorable CV profile [Sandrini et al. 2012; Bakar et al. 2009; Webster et al. 2005a]. In addition to renal injury from prolonged use, other major adverse effects of CNI are hypertension, NODAT and dyslipidemia [Nankivell et al. 2004; Bloom and Reese, 2007]. These events are more likely to occur with the combined treatment of CNI and larger doses of steroids [Lloberas et al. 2008].

Similarly, CNI has been implicated in the promotion of endothelial dysfunction accounting for the impairment in glomerular filtration rate (GFR), cardiac allograft vasculopathy and perhaps contributes to long-term CV morbidity [Yong et al. 2013; Nankivell et al. 2004; Bloom and Reese, 2007]. In a prospective crossover trial, compared with renal recipients switched to SRL, after 5 months of TAC those maintained on the CNI had lower surrogate indices of CV disease that included pulse wave velocity and an aortic augmentation index that was adjusted for heart rate. However as discussed below such short-term benefit of noncalcineurin inhibitor agents has consistently failed to translate into a superior allograft survival in most studies [Guethoff et al. 2015; Zsom et al. 2015].

The concern that drug-related metabolic (and renal) disorders might shorten allograft survival has led to the use of CNI minimization protocols [Zsom et al. 2015; Gallagher et al. 2004; Lebranchu et al. 2009; Holdaas et al. 2011; Budde et al. 2011]. In this regard, the dose of CNI is either reduced or the drug is substituted with an alternative agent (e.g. SRL) at an early or late phase of the transplant. However, such an approach may result in a greater frequency of late-onset AR events [Wang et al. 2013; Burkhalter et al. 2012]. Consequently there may be need for a greater amount of steroid rescue treatments, which in turn may promote metabolic disturbances. In recent times, critical analysis of pre-existing data is refuting the significant role of drug-induced nephrotoxicity in late-onset graft losses while emphasizing the negative impact of de novo generation of donor specific antibodies. Hence rather than the untoward effect of excessive treatment with CNI, inadequate immune suppression may be more deleterious to graft survival [Zsom et al. 2015].

Sirolimus

Because of its antiproliferative effect, there was an initial enthusiasm that SRL might attenuate interstitial fibrosis and therefore prolonged allograft survival. Additional justification for using SRL in place of CNI was rooted in its ability to suppress replication of BK polyomavirus (and therefore prevent BK nephropathy) by interfering with mTOR-S6-Kinase activity [Hirsch et al. 2015]. It is also known for reduction of the more frequent occurrence of nonmelanoma carcinoma in SOT recipients [Tessari and Girolomoni, 2012]. However in the SYMPHONY trial, SRL was associated with the highest rate of AREs. Although there was improvement in transplant function after early substitution of CNI for SRL (3–6 months), there was no allograft survival benefit particularly in the setting of a pre-existing low GFR or proteinuria [Zsom et al. 2015; Ekberg et al. 2007; Chhabra et al. 2012; Lyster et al. 2004]. In addition SRL failed to improve the graft survival when used in combination with CNI [Ekberg et al. 2007; Chhabra et al. 2012]. Rather it increased the propensity of CNI to produce nephrotoxicity, thrombotic microangiopathy, NODAT, and dyslipidemia [Lloberas et al. 2008; Benfield et al. 2010]. Due to the failure of SRL to meet the high expectations of the transplant community and the unexpected high rate of side effects, there has been a downward trend with its use in the last two decades [Lyster et al. 2004; Pape and Ahlenstiel, 2014].

Mycophenolate mofetil

MMF has no direct metabolic effect but its use may reduce the total amount of steroids, SRL and CNI required for immunosuppression. In a randomized clinical trial (RCT) of steroid minimization strategy, exclusion of MMF caused a higher rate of AREs and a two-fold increase in short-term allograft losses [Knight et al. 2009]. Similarly, patients with single nucleotide polymorphism for uridine diphosphate glucuronosyl-transferase (UGT2B7), the metabolizing enzyme for MMF, experienced higher rate of AREs [Pazik et al. 2013]. In the absence of therapeutic drug monitoring, as it is currently practiced, lower bioavailability of MMF due to such polymorphism may lead to a greater need for steroids or CNI. Studies are needed to validate this hypothesis and to determine if there are metabolic and CV consequences. A proof of significant adverse clinical outcome may justify either therapeutic drug monitoring or avoidance of MMF in this population subset.

Belatacept

Belatacept is a CTLA4Ig fusion protein that blocks costimulatory activation of CD28 receptors on T cells. Compared with CsA, it produces a higher rate of early-onset AREs, greater preservation of 12-month allograft function but a similar rate of 5-year graft survival rate [Rostaing et al. 2013]. In addition, using 7-year risk calculators derived from the ALERT trial, belatacept was projected to reduce major adverse CV events by >20%, and lower the mortality rate by 18–30% [Soveri et al. 2013]. Concern for renal toxicity and metabolic dysregulation has also led to the successful substitution of belatacept for CNI after more than 6 months of treatment [Rostaing et al. 2011; Paz et al. 2014]. In a more recent meta-analysis, belatacept produces a better control of blood pressure, more favorable lipid profiles, and a lower incidence of NODAT in comparison with patients treated with CNI [Masson et al. 2014]. Nevertheless, despite a lower occurrence of chronic allograft fibrosis, there is no difference in either patient or allograft survival rate over a 3-year study period. A longer clinical experience with belatacept will provide an opportunity to evaluate if such metabolic benefits will translate into a long-term CV advantage [Masson et al. 2014; Le Meur et al. 2011].

Steroids and oxidative stress

In renal transplantation, oxidative stress often occurs in two clinical settings. As demonstrated in experimental studies, reactive oxygen species are generated in response to reperfusion injury as produced by a frequent event of prolonged cold ischemia time prior to transplant surgery in deceased solid organ donation [Turgay et al. 2012]. Pulse treatment with methyl prednisolone given during transplant surgery may attenuate such proinflammatory oxidative responses. Unlike this beneficial effect, chronic administration of steroids in high dose produces persistent oxidative milieu by inducing carbonylation of skeletal muscle protein [Saidi et al. 2007]. This event may favor the development of hypertension, diabetes mellitus and accelerated atherosclerosis [Calò et al. 2002]. Paradoxically, treatment with low steroid doses on a chronic basis, as currently used in many transplant programs, may downgrade such pro-oxidative tissue inflammation [Saidi et al. 2007].

Steroids, calcineurin inhibitors and hypertension

The prevalence rate of hypertension in adults with renal transplant ranges from 50–80% while that of pediatric recipients varies from 47–82% [Weir et al. 2015]. Poor blood pressure control is not uncommon thereby justifying the need for multiple antihypertensive agents [Kislikova et al. 2015]. This may result in shorter duration of allograft survival and may translate into long-term CV mortality [Weir et al. 2015; Kislikova et al. 2015; Rossi and Vella, 2015]. Treatment with ISAs influences the occurrence of modifiable predictors of hypertension, namely exogenous obesity and AREs [Rossi and Vella, 2015]. Aside from steroid contribution and excessive deposition of fat mass, similar to CNI, it causes proangiotensinogen vasoconstrictive endothelial dysfunction [Calò et al. 2002; Rossi and Vella, 2015; Sander et al. 1996; Pourmand et al. 2015; Bailey et al. 2009; Baum and Moe, 2008]. On the other hand, inadequate treatment with ISAs intensifies recurrent AREs which may result in chronic renal allograft injury and therefore promotes a secondary form of hypertension.

Although steroid suppression of inflammatory cytokines attenuates a hypertensive response to an oxidative state, a dose-dependent vasoreactive effect may override such benefits [Sander et al. 1996]. In addition, due to pre-existing vasculopathy, steroid use, and vasoconstrictive effects of CNI, hypertension is common in the first few days after renal transplant [Sander et al. 1996; Pourmand et al. 2015]. In a few instances, persistent fluid retention due to delayed graft function may contribute to accelerated hypertension. However, the role of fluid retention as a mediator of steroid-induced hypertension may be overstated. An experimental mouse model of chronic steroid use (adrenocorticotrophic hormone [ACTH] infusion) suggests there is only a minimal role for mineralocorticoid activity [Bailey et al. 2009]. Microarray analysis showed no remarkable change in the renal expression of mineralocorticoid target genes including epithelial cell sodium channel (ENaC), SCNN1A, KRAS, AND NEDD4. Indeed there was no evidence for tubular sodium reabsorption, potassium wasting or elevation in plasma renin activity [Bailey et al. 2009]. Rather there was net sodium excretion due to the combined effect of glomerular hyperfiltration and inhibition of proximal tubule reabsorption.

A more plausible explanation for steroid-induced hypertension is its inhibition of nitric oxide (NO) synthesis. This was experimentally demonstrated by the blockade of steroid-promoted hypertension after an infusion of L-arginine [Baum and Moe, 2008]. Similar to CNI, it is postulated that steroids may increase vasoactive response to angiotensin II by enhancing synthesis of GC receptors on endothelial smooth muscle cell [Pourmand et al. 2015; Baum and Moe, 2008]. Hence knock-out mouse of endothelial GC receptors failed to develop hypertension in response to dexamethasone infusion [Baum and Moe, 2008]. Finally, the modulatory role of oxidative stress in steroid-induced hypertension was suggested by the concurrent attenuation of both oxygen radicals and hypertension after treatment with ramipril [Calò et al. 2002].

Steroids and obesity

In children and adults alike, there is an increasing prevalence of exogenous obesity often with an onset in the first year of solid organ transplantation [Denburg et al. 2010; Hoogeveen et al. 2011; Hanevold et al. 2005]. In a retrospective cohort study, the prevalence rate of obesity increased from 13% at baseline to >30% after 3 months of renal transplantation [Denburg et al. 2010]. Numerous studies support the etiological role of the cumulative dose of steroids in post-transplant obesity [Denburg et al. 2010; Hoogeveen et al. 2011; Hanevold et al. 2005; Foster et al. 2010; Vester et al. 2005]. In one of such studies, there was a significant positive correlation between GC exposure and the Z-score of the body mass index (BMI) [Denburg et al. 2010]. In addition to steroid use, other risk factors for persistent obesity after transplant are younger age group, remote transplant year, maternal obesity, female gender, lower baseline BMI, and ethnic minority [Boschetti et al. 2013; Denburg et al. 2010; Foster et al. 2010; Vester et al. 2005]. Apparently due to its relationship with hepatoportal circulation, truncal adiposity generates proinflammatory milieu by secreting adipokines such as leptin, IL-6 and TNF-a [Hajer et al. 2008; Lambert et al. 2010]. On the other hand, hyperleptinemia promotes insulin resistance; it causes an increase in fasting plasma insulin, post-prandial hyperglycemia and decreased mRNA expression of insulin receptors in skeletal muscle [Wjidan et al. 2015]. As part of metabolic syndrome, there is an increase in the activation of the renal sympathetic system, which in turn causes renin-mediated hypertension [Lambert et al. 2010].

Although the confounding effect of pulse steroid treatment of AREs cannot be excluded, excessive weight gain after SOT is predictive of lower rates of both graft and patient survival [Boschetti et al. 2013; Hoogeveen et al. 2011]. Indeed preadolescent renal patients with post-transplant obesity are at higher risk of death from cardiopulmonary disease and graft loss from thrombosis [Hanevold et al. 2005]. Similarly, there is higher mortality rate in lung transplant recipients with obesity [Upala et al. 2015] and in liver transplant patients with greater amount of abdominal adiposity [Terjimanian et al. 2015]. However, a recent meta-analysis suggests there may be improving survival of allograft recipients in the modern era compared with those transplanted before the year 2000 [Nicoletto et al. 2014].

Steroid-induced new onset diabetes after transplant

Most data on the predisposing factors of NODAT support the etiological role of the cumulative dose of steroids [Cole et al. 2013; Schweer et al. 2014]. Indeed the falling incidence of NODAT in recent times may be related to the lower utilization of steroids in many programs [Cole et al. 2013; Schweer et al. 2014; Hjelmesaeth et al. 1997; Luan et al. 2011]. A study showed there is a 5% risk of developing diabetes mellitus for every 0.01 mg/kg/day increase in prednisolone dose [Hjelmesaeth et al. 1997]. Similarly, there is a 42% greater risk of developing NODAT in patients placed on a steroid-based regimen over a period of 3 years [Luan et al. 2011]. However, there have been few studies of high quality that failed to confirm the diabetogenic effect of steroids [Pascual et al. 2012]. In a RCT, although there was no difference in the frequency of NODAT, a greater proportion of patients treated with steroids required insulin (indicating metabolic severity) for the control of diabetes [Woodle et al. 2008].

Perhaps one reason for the disparity in study outcomes is the variation in the diagnostic criteria for post-transplant diabetes [Langsford and Dwyer, 2015]. Furthermore, the benefit derived from a steroid-sparing regimen may be offset by the harmful metabolic effect of the greater need of CNI to prevent AREs in the control arms [Schweer et al. 2014; Webster et al. 2005b]. As for the pathogenesis, GC produces hyperglycemia by inducing the transcription genes for hepatic gluconeogenic enzymes [Vadlamudi et al. 1993] (Table 1). Hence, the initial functional inhibition of beta cells by steroids is overcome by glucose-induced hyperinsulinemia. However, an excessive amount of insulin is invariably cytotoxic; it inhibits the replication of the pancreatic islet cells. Similarly synergistic cytotoxic injury may be produced by the larger doses of a concurrent treatment with CNI [Choi et al. 2006]. Ultimately, persistent stimulation of a fewer number of beta cells causes pancreatic cell hypertrophy (and established diabetes mellitus).

Calcineurin inhibitor and new onset diabetes after transplant

Compared with CsA, there is a 25% greater incidence of NODAT in patients treated with maintenance TAC [Luan et al. 2011]. There is a dose–effect relationship such that greater exposure of CNI results in higher incidence of NODAT [Chan et al. 2012]. However, compared with lower doses of CsA and SRL, low-dose TAC has the greatest potential for NODAT [Ekberg et al. 2007]. In addition, transplant recipients with prevailing hyperlipidemia, a traditional CV risk factor, are more likely to sustain CNI-induced diabetes mellitus [Porrini et al. 2008]. On the other hand, early discontinuation or reduction in the dose of CNI may reverse the diabetic complication [Veroux et al. 2013]. The mechanism by which CNI induces diabetes mellitus involves multiple concurrent variables (Table 1 and Figure 1). Hypomagnesemia, a common side effect of CNI, impairs pancreatic insulin secretion by increasing calcium concentration within the beta cells [Rodríguez-Morán and Guerrero-Romero, 2011]. Similarly, free cytosolic calcium ions in other cells may promote insulin resistance by the activation of protein kinase C, a constitutive regulator of insulin receptor substrate [Rodríguez-Morán and Guerrero-Romero, 2011].

OPEN IN VIEWER

Figure 1.

Mechanisms of calcineurin-inhibitor induction of pancreatic beta cell toxicity in new onset diabetes mellitus after transplant.

Furthermore, CNI prevents dephosphorylation of cytoplasmic nuclear factor of activated T cells (NFATc), a transcription factor for genes that promotes islet cell proliferation [Rostambeigi et al. 2011]. By a similar mechanism it reduces the efficiency of insulin secretion by causing functional alteration of glucokinase enzyme [Rostambeigi et al. 2011; Penfornis and Kury-Paulin, 2006]. Albeit in high doses, in vitro treatment with CsA has also been shown to produce direct pancreatic toxicity by inducing apoptosis of beta cells [Penfornis and Kury-Paulin, 2006]. Apart from the deficient pancreatic secretion of insulin, end-organ resistance is depicted by the inhibition of glucose uptake by human adipocytes exposed to therapeutic doses of both CsA and TAC [Pereira et al. 2014]. This metabolic effect is mediated by the endocytic removal of glucose transporter type 4 (GLUT4) from the cell surfaces, and it is independent of insulin signal transduction.

Sirolimus and new onset diabetes after transplant

Perhaps due to the variation in study quality, data on the role of SRL in the etiology of NODAT showed inconsistent result [Veroux et al. 2013; Johnston et al. 2008; Gyurus et al. 2011; Teutonico et al. 2005]. In an analysis of a US registry, compared with its combination with MMF, addition of SRL to CNI increases the risk of developing NODAT [Johnston et al. 2008]. Older recipients of renal transplants are more susceptible to SRL-induced diabetes mellitus [Gyurus et al. 2011]. However, not all studies affirmed the diabetogenic effect of SRL. In one study, after switching patients from a CNI-based protocol to SRL, there was no difference in the outcome of an oral glucose tolerance test [Teutonico et al. 2005]. Furthermore, compared with CNI, the diabetogenic response to SRL may be less intense. Hence its substitution for CNI has led to the resolution of NODAT in some instances [Veroux et al. 2013].

Demonstrating a biphasic biologic effect, acute SRL treatment enhances insulin sensitivity by inhibition of the mTOR complex 1 (mTORC-1) [Table 1, Figure 2]. Paradoxically, its chronic use produces insulin resistance by the disruption of mTORC-2. Activation of mTORC-1 by cellular exposure to excessive nutrients promotes insulin resistance by enhancing (serine) phosphorylation of IRS-1. The latter in turn decreases the activation of phosphatidyl inositol 3-kinase, and thereby creates a negative feedback loop for insulin action [Houde et al. 2010]. By blocking mTORC-1, SRL produces a starvation-like signal despite nutrient abundance and was therefore considered a potential therapeutic agent for attenuating insulin resistance. However, a paradoxical effect of glucose intolerance and hyperlipidemia was observed with its use in transplant recipients [Houde et al. 2010]. This is because chronic treatment with SRL produces hyperglycemia by overriding the inhibitory effect of insulin on the transcription of hepatic gluconeogenic enzymes.

OPEN IN VIEWER

Figure 2.

Biphasic effect of sirolimus: acute treatment enhances insulin sensitivity while chronic dosing causes insulin resistance.

Steroids and dyslipidemia

Chronic steroid use increases free fatty acid synthetase and upregulates hepatic synthesis of very low-density lipoprotein (VLDL) (Table 2). It also reduces the synthesis of low-density lipoprotein (LDL) receptor and inhibits the activity of lipoprotein lipase [Razeghi et al. 2011]. The sum effect is an increase in serum total cholesterol, high serum triglyceride, elevated level of VLDL but a reduction in plasma high-density lipoprotein (HDL) cholesterol [Ferraris et al. 2007].

OPEN IN VIEWER

Table 2.

Pathogenesis of dyslipidemia due to immunosuppressive agents.

Immunosuppressive agents	Pathogenesis of dyslipidemia	Pattern of dyslipidemia
Steroids	Increases FFA synthetase	Increases plasma total cholesterol Increases plasma triglyceride Increases plasma VLDL Reduces plasma HDL
	Reduces LDL receptor
	Reduces lipoprotein lipase activity
Calcineurin inhibitors: TAC/ CsA	CsA inhibits mitochondrial 27-hydroxylase and increases HMGR activity	Increases plasma total cholesterol Increases VLDL Increases LDL Increases plasma TG
	CsA binds LDL receptor
	Increases hepatic lipase and reduces lipoprotein lipase
Sirolimus/ everolimus	Reduces hepatic lipase but increases lipase enzyme in adipocytesDownregulates peroxisome proliferator-activated receptor-γ 2 (PPAR-γ 2)	Increase total plasma total cholesterol Increases plasma TG Increases plasma LDL Increases ApoB-100

CsA, cyclosporine; FFA, free fatty acid; HDL, high-density lipoprotein; HMGR, 3 hydroxy - 3-methyl-glutaryl-CoA reductase; LDL, low-density lipoprotein; TAC, tacrolimus; TC, total cholesterol; TG, triglyceride; VLDL, very low-density lipoprotein.

and dyslipidemia

CsA causes dose-dependent inhibition of mitochondrial 27-hydroxylase (CYP27A1) and therefore increases the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), a key regulatory enzyme in cholesterol synthesis [Gueguen et al. 2007] (Table 2). CsA impairs the clearance of VLDL and LDL cholesterol by binding to the LDL receptor. In addition, it increases the activity of hepatic lipase, which in turn converts intermediate-density lipoprotein to LDL. It also downregulates lipoprotein lipase enzyme activity [Derfler et al. 1991; Sugioka et al. 2006]. Furthermore, CsA is transported in the circulation by LDL cholesterol particles, which facilitates its intracellular uptake by LDL receptors. CsA effect on lipid metabolism is facilitated by the concurrent use of high-dose steroids. Elevated cytoplasmic concentration may promote endothelial inflammation by increasing the susceptibility of LDL cholesterol to oxidative milieu [Gueguen et al. 2007]. On the other hand, compared with CsA, TAC produces less lipid disturbances. Indeed a switch to TAC from a CsA-based regimen is associated with resolution of hyperlipidemia [Bakar et al. 2009].

Depicting its role in the regulation of lipid homeostasis, mice lacking calcineurin Aβ (CnAβ) developed hyperlipidemia [Suk et al. 2013]. Calcineurin is associated with greater degree of lipolysis in adipose tissues, a process mediated by the β-adrenergic G-protein-coupled receptor signaling pathway and sustained by intracellular activation of cyclic AMP and protein kinase A [Suk et al. 2013]. Knock-out mice (CnAβ) developed hyperlipidemia by enhancing the signal transduction and by upregulation of the metabolic pathway. CsA toxicity may be aggravated by a higher serum level of saturated fatty acid, which may be seen in patients with steroid-induced obesity and drug-induced hyperlipidemia [Luo et al. 2012]. This was demonstrated in an experimental study in which cotreatment of hepatic cells with palmitic acid and CsA caused dose-dependent cytotoxicity and apoptosis. The cellular injury was associated with mitochondrial dysfunction and may be mediated by activation of c-Jun N-terminal kinase (JNK).

Sirolimus and dyslipidemia

Sirolimus increases lipase enzyme activity in adipose tissue but causes a reduction in the synthesis of hepatic lipoprotein lipase (Table 2). At 2 weeks after addition of SRL to the regimen of CsA and prednisone in transplant recipients, there is a dose-dependent increase in total plasma cholesterol, plasma LDL, serum triglyceride, and ApoB-100 [Morrisett et al. 2003]. Normal lipid levels are restored by about 4 weeks after discontinuation of the drug [Spinelli et al. 2011; Morrisett et al. 2003]. In animal models, SRL impairs circulating triglyceride hydrolysis (lipoprotein lipase), cellular fatty acid uptake, and lipid synthesis (lipin 1) by downregulation of peroxisome proliferator-activated receptor-γ 2 (PPAR-γ 2) [Houde et al. 2010] (Table 2). It blocks the modulatory effects of mTORC-1 on adipogenesis through the AKT-mediated phosphorylation of tuberous sclerosis complex 2. Consequently, the reduction in the capacity of adipose tissue clearance of fat results in hyperlipidemia [Houde et al. 2010]. Paradoxically, prolonged SRL treatment in experimental animals causes a reduction in food intake and weight loss while there is an increase in energy expenditure.

Steroids and linear growth

The initial wave of clinical trials on steroid minimization was conducted in pediatric populations out of concern for its negative impact on longitudinal skeletal growth in children. A 2-year RCT of late steroid withdrawal (>3 months) using CsA and MMF as a maintenance therapy showed a positive catch-up growth and a favorable metabolic impact [Höcker et al. 2010]. In a 2-year follow up of a similar study, the skeletal growth advantage was sustained, and it was observed as more pronounced in prepubertal children [Webb, 2015] However, compared with the control, there was no difference in AREs, nor in patient or allograft survival.

Steroids and bone disease

Despite normal serum calcium, phosphorous and intact parathyroid hormone (PTH) in transplant recipients, osteitis fibrosa, osteomalacia, and adynamic bone disease are commonly observed on evaluation by bone biopsy [Evenepoel, 2013]. Observational study showed there was a positive correlation between cumulative steroid doses, accelerated cancellous bone remodeling, and loss of bone mineral density [Pichett et al. 1996; Julian et al. 1991]. Steroids produce a negative calcium balance by reducing intestinal absorption while increasing its urinary excretion [Canalis et al. 2007]. This metabolic aberration may impair the restoration of pretransplant hyperparathyroidism. In addition, onset of chronic allograft dysfunction may lead to a persistent metabolic acidosis, 1, 25 vitamin D deficiency, and a more rapid progression of bone disease [Evenepoel, 2013]. Perhaps for these reasons, vertebral fracture occurs at a higher rate than in the general population as observed in a cross sectional study [Jiménez et al. 2015]. Its higher frequency of occurrence also correlates with greater cumulative dose of steroids and a longer pretransplant duration of dialysis [Patel et al. 2001]. However, there is a failure to confirm the predictive relationship of bone fracture with steroid use in studies with long-term follow up [Malluche et al. 2010; O’Shaughnessy et al. 2002].

Steroid decreases bone-forming osteoblastic cells, increases osteocyte apoptosis, and attenuates both insulin-like growth factor-1 (IGF-1) and transforming growth factor-β (TGF-β). It causes bone resorption by stimulating osteoprotegerin ligand (OPG-L) and promotes inactivation of osteoprotegerin (OPG), a soluble neutralizing receptor [Hofbauer et al. 1999]. Lower doses of steroids, its use as alternate-day regimen, and correction of hypogonadism may ameliorate the severity of bone disease [Weisinger et al. 2006]. In addition, patients on a GC-withdrawal protocol had a net gain in bone mineral density; a benefit that was more pronounced in patients with severe kidney disease [Ing et al. 2011]. There are limited data on the safety and effectiveness of bisphosphonates in transplant settings. In a prospective study of liver transplant recipients, trabecular bone mineralization was preserved while there was no beneficial effect on the cortical bone mass [Pennisi et al. 2007].

Calcineurin inhibitors, sirolimus and bone metabolism

Due to concurrent use of CNI with steroids, studies on their solitary effect on bone metabolism are limited [Malluche et al. 2010; Marcén et al. 2006; Briner et al. 1995]. Confounding effects of steroid use may account for the conflicting outcome of the clinical studies. Both TAC and CsA stimulate osteoclastic activity in excess of deficit in osteoblastogenesis, and therefore enhance cancellous bone loss [Kirino et al. 2004]. Elevation in serum PTH, increased serum alkaline phosphatase, a rise in serum osteocalcin, and hyperparathyroid bone changes in the face of normal value of 1, 25-dihydroxyl vitamin D level suggest there is a skeletal end-organ resistance [Briner et al. 1995; Kirino et al. 2004]. Despite the proof of higher bone turnover rate, there is no evidence for a greater risk of skeletal fracture with the use of these agents [Patel et al. 2001]. On the other hand, in vitro studies showed mTOR inhibitor (SRL and EVR) enhances osteoblast differentiation by inactivation of notch pathway and upregulation of Runx2 [Huang et al. 2015]. It also decreases the formation of osteocytes with a resultant preservation of cancellous bone mass [Kneissel et al. 2004].